BMS 181102

Drug Profile

BMS 181102

Latest Information Update: 17 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-ischaemics
  • Mechanism of Action Calcium channel antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 14 Mar 2001 No-Development-Reported for Neurological disorders (Prevention) in USA (Unknown route)
  • 15 May 1995 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top